BDC Capital and SR One leads Series D round for Thrasos
Montreal-based Thrasos Therapeutics, a biotherapeutics company focused on kidney disease, has closed $21 million in Series D funding. BDC Capital and SR One led the round. In conjunction with the funding, Ela Borenstein, a manager partner at BDC, has been added to the Thrasos board of directors.
31 March 2015•4 mins read
